Dana-farber Cancer Institute

This study tested a drug called abemaciclib in 27 people with a specific type of advanced breast cancer (triple-negative, retinoblastoma-positive). The goal was to see if the drug could shrink tumors or slow the cancer's growth. The trial was terminated early, so results are limi…

This study tested a drug called neratinib, alone or with another drug called fulvestrant, in 21 people with a specific type of advanced breast cancer (HER2-positive and ER-positive). The goal was to see if the combination could slow cancer growth. The study was stopped early, but…

This study tested two immunotherapy drugs, ipilimumab and nivolumab, as a first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs worked and to find markers that predict response. Only 5 people enrolled before th…

This study tested two immunotherapy drugs, durvalumab and tremelimumab, in people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial enrolled 19 participants whose cancer had worsened after standard chemotherapy. The goal was to see if the drug combi…

This study tested a new drug, GDC-0084, combined with the standard drug trastuzumab (Herceptin) in 17 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the combination could shrink or control brain tumors. The trial was terminated early,…

This study tested whether adding the immunotherapy drug avelumab to standard radiation could help treat muscle-invasive bladder cancer in patients who cannot receive the usual chemotherapy. Fourteen participants received the combination therapy. The goal was to see if the cancer …